BACKGROUND: The objective of this work was to evaluate prevalence of eosinophilic esophagitis (EoE) in the United States, and analyze prevalence of atopic disease in patients with EoE. The study design was a retrospective administrative database analysis in U.S.-based outpatient settings. METHODS: A retrospective claims analysis in the inpatient and outpatient setting (using MarketScan) was conducted to analyze prevalence of atopic disease diagnoses in patients with EoE in 2012, and timing of those diagnoses vs EoE. RESULTS: From published evidence, prevalence of EoE was estimated at 1 to 5 patients per 10,000 and prevalence of asthma, allergic rhinitis (AR), and atopic dermatitis (AD) concurrent to EoE ranged from 20% to 50%, 50% to 75%, and 2% to 19% cases, respectively. From 2009 and 2013, the estimated prevalence of EoE in MarketScan increased from 2.7 to 5.6 per 10,000 enrollees age 34.5 ± 18.43 years (mean ± standard deviation). Age followed a bimodal distribution with peaks at 12 and 41 years. Women accounted for 35.6% cases. Prevalence of asthma, AR, AD, and food allergies up to 12 months post-EoE diagnosis reached 44.7%, 27.1%, 25.2%, and 16.9%, respectively, with 63.5% of all patients suffering from at least 1 of these 4 diseases and 3.0% suffering from all 4. CONCLUSION: The diagnosis of EoE is associated with the diagnoses of asthma, AR, AD, and food allergies. The high prevalence of these conditions in EoE patients further strengthens the hypothesis of a common pathogenesis.
BACKGROUND: The objective of this work was to evaluate prevalence of eosinophilic esophagitis (EoE) in the United States, and analyze prevalence of atopic disease in patients with EoE. The study design was a retrospective administrative database analysis in U.S.-based outpatient settings. METHODS: A retrospective claims analysis in the inpatient and outpatient setting (using MarketScan) was conducted to analyze prevalence of atopic disease diagnoses in patients with EoE in 2012, and timing of those diagnoses vs EoE. RESULTS: From published evidence, prevalence of EoE was estimated at 1 to 5 patients per 10,000 and prevalence of asthma, allergic rhinitis (AR), and atopic dermatitis (AD) concurrent to EoE ranged from 20% to 50%, 50% to 75%, and 2% to 19% cases, respectively. From 2009 and 2013, the estimated prevalence of EoE in MarketScan increased from 2.7 to 5.6 per 10,000 enrollees age 34.5 ± 18.43 years (mean ± standard deviation). Age followed a bimodal distribution with peaks at 12 and 41 years. Women accounted for 35.6% cases. Prevalence of asthma, AR, AD, and food allergies up to 12 months post-EoE diagnosis reached 44.7%, 27.1%, 25.2%, and 16.9%, respectively, with 63.5% of all patients suffering from at least 1 of these 4 diseases and 3.0% suffering from all 4. CONCLUSION: The diagnosis of EoE is associated with the diagnoses of asthma, AR, AD, and food allergies. The high prevalence of these conditions in EoE patients further strengthens the hypothesis of a common pathogenesis.
Authors: C Górriz Gil; V Matallana Royo; Ó Álvarez Montero; A Rodríguez Valiente; C Fernández Manzano; B Conde García; J R García-Berrocal Journal: HNO Date: 2018-07 Impact factor: 1.284
Authors: Leah C Kottyan; Michael P Trimarchi; Xiaoming Lu; Julie M Caldwell; Avery Maddox; Sreeja Parameswaran; Michael Lape; Rahul J D'Mello; Madeline Bonfield; Adina Ballaban; Vincent Mukkada; Philip E Putnam; Pablo Abonia; Netali Ben-Baruch Morgenstern; Amy A Eapen; Ting Wen; Matthew T Weirauch; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2020-10-23 Impact factor: 14.290
Authors: Jonathan Wong; Sue Goodine; Kate Samela; Katherine S Vance; Beth Chatfield; Zhu Wang; Wael N Sayej Journal: Pediatr Gastroenterol Hepatol Nutr Date: 2020-01-09
Authors: José Antonio Cañas; Ana Tabares; Claudia Barbero; Daniel García-Sánchez; Beatriz Sastre; José Manuel Rodrigo-Muñoz; Ignacio Mahíllo-Fernández; Ana Rayo; Belén Borrell; Mª Luz Cilleruelo; Enriqueta Román; Sonia Fernandez-Fernandez; Carolina Gutiérrez-Junquera; Victoria Del Pozo Journal: J Pediatr Gastroenterol Nutr Date: 2020-12 Impact factor: 3.288